The deal
Swedish buyout firm EQT is in advanced talks to acquire Qiagen, the European molecular-testing company, Bloomberg News reported on October 20, 2026, citing people familiar with the matter. EQT has submitted a binding offer of more than $50 per share for Qiagen — implying a valuation north of €9 billion against Qiagen's €8.57 billion market capitalization (per LSEG data).
EQT is not alone: US private equity giant KKR has also made a bid, setting up a potential two-way contest for one of Europe's most important diagnostics companies. Qiagen's board is meeting this week to decide on the potential deal. US-listed shares of Qiagen rose more than 6% in afternoon trading on the news.
There is no certainty the discussions will lead to a sale to EQT or another buyer. Qiagen said it does not comment on "market rumors or speculation"; EQT did not immediately respond to requests for comment, and KKR declined to comment.
Background and context
This is not a bolt from the blue. Qiagen said in January 2026 that it was evaluating strategic options amid renewed takeover interest, and buyout firms including EQT, Advent, and KKR were linked to a potential acquisition as far back as July. The October 20 report suggests the process has now moved from exploratory to decisive — a binding offer on the table and a board meeting this week.
Qiagen, headquartered in the Netherlands, develops molecular testing and sample-preparation technologies used by research and clinical laboratories worldwide. It sits at a strategically valuable intersection: diagnostics is one of the few healthcare segments with both defensive demand characteristics and genuine technology-driven growth, as molecular testing expands from research labs into routine clinical use.
The bidder lineup tells its own story. EQT, one of Europe's largest private equity firms, has been aggressively building its healthcare portfolio; KKR is no stranger to large European healthcare take-privates. When two firms of this caliber both submit bids, it signals shared conviction that Qiagen's assets are worth materially more in private hands. Barclays analyst Luke Sergott said a deal appears "more likely," reiterating his $55 price target — above EQT's reported bid, hinting the price could still move up.
Deal mechanics and key terms
- Bid: EQT's binding offer of more than $50 per share; KKR has submitted a competing bid (terms undisclosed).
- Implied value: €9 billion-plus at $50+/share vs. €8.57B market cap — a premium in the high single digits at minimum, with Barclays' $55 target implying room for a bump.
- Process stage: Advanced talks; board deliberating this week; no certainty of a sale.
- Market read: US shares up >6% on the report — meaningful deal probability priced in, but the modest pop reflects genuine uncertainty and the chance the board rejects both bids.
- Timeline: Qiagen has been "evaluating strategic options" since January — a ten-month process approaching its endgame.
The binding nature of EQT's offer matters: unlike an indicative proposal, a binding bid typically means financing is lined up and terms are largely settled, leaving the board's decision as the main gating item. KKR's rival bid gives the board leverage — and gives EQT a reason to move fast.
Why it matters for founders
For founders in diagnostics, life-sciences tools, and healthcare IT, the Qiagen saga is a reminder that strategic-option processes are marathons. Qiagen announced its review in January; the endgame arrived in October. Founders running their own sale processes should plan for 6–12 months, keep the business performing throughout, and understand that "no certainty" language from the company is standard.
Second, competitive tension is the founder's best friend in any exit. A single bidder negotiates down; two bidders bid up. Barclays' $55 target sitting above EQT's $50+ bid is the market pricing in exactly that dynamic — engineer your process to produce multiple credible bidders.
Why it matters for investors
For public investors, Qiagen is now a classic event-driven situation: shares trade at a discount to the $50+ bid, reflecting deal uncertainty. The spread compensates for two risks — the board walking away, and regulatory review of a €9B+ European healthcare asset. Barclays' $55 target suggests the street sees a plausible bump if KKR counters.
For private investors, the bigger signal is the continued appetite for large European healthcare take-privates. EQT and KKR circling the same asset at €9B+ shows mega-funds still see double-digit return potential in mature diagnostics — operational improvement plus the long-run growth of molecular testing in clinical practice. If you hold European medtech or life-sciences tools positions, your comp set just got a fresh, very public data point.
Watch the board meeting this week. A "yes" triggers a formal offer and a shareholder vote; a "no" likely sends shares back down — but with two motivated bidders, "no" may just mean "not at this price."
Angeled.com connects founders with investors.
Source: EQT in Advanced Talks to Acquire Qiagen Amid Competing Bids — Global Banking and Finance
Read Next
Inovalon to Acquire DrFirst, Uniting Healthcare Data With Prescribing Workflows
Oura to Acquire Counsel Health for $625 Million, Putting a Doctor Behind the Ring
Anthropic Files Updated IPO Prospectus Aiming at a $1.4 Trillion Valuation
Archrock to Acquire HiVolt Energy for Up to $450 Million
Barrick Mining Files to Spin Off and List Its North American Gold Business
What a $1.4 Trillion Anthropic IPO Would Mean for Founders



